Paper Title
Normalization of Genome Instability in Pulmonary Tuberculosis

Abstract
Pulmonary Tuberculosis (PT) is classified as a disease with a hereditary predisposition. Genetic factors contribute to the outcome of primary PT infection, with an estimated heritability of more than 50%[1,2]. The genotype of an organism plays an important role in the development of PT diseases. Numerous studies have been performed to identify genetic factors responsible for variation in PT susceptibility[3]; however, none of the candidate genes was associated with susceptibility to active PT[4,5]. Therefore, as with all the pathologies related to this group, particular importance is attached to finding those markers that enable early detection of high-risk groups of the disease in the population. Data on the variability of such informative and important functional parameters, which are associated with the epigenetic processes in PT, are practically absent. The aim of our study was to evaluate genetic and epigenetic variation of the genome in patients with sensitive Pulmonary Tuberculosis (PT) before and after treatment, under the effect of peptide bioregulator–Ala-Glu-Asp-Gly. In lymphocyte cultures from patients with sensitive primary PT were studied: facultative heterochromatin (sister chromatid exchanges - SCE) and the level of mutation(chromosome aberrations). We determined: There was an epigenetic alteration of functional parameters of the genome in PT before treatment. The level of heterochromatin decreased in the telomeric regions of chromosomes - A1,A2,B,C,D,F and G groups (in control it was high) and increased in the middle regions of chromosomes - A1,B,C,E,F, and G groups (in control it was reduced); There was a high level of somatic recombination; Revealed an increase of the frequency of cells with chromosome aberrations. The bioregulator (Ala-Glu-Asp-Gly) has normalized the modified genomic parametersand it could be used as an aid in the prevention and treatment of tuberculosis [6]. Reduction of heterochromatinization in telomeric regions and an increase in the middle region of chromosomal arms (change of histone-DNA contacts) and an increase in chromosome aberrations before treatment make it possible to use such chromatin modifications as PT biomarkers and may lead to the development of therapeutic treatment [6]. Keywords - Pulmonary Tuberculosis; Heterochromatinization; Genome Instability.